Bank of America
CCCC icon

Bank of America’s C4 Therapeutics CCCC Stock Holding History

Bank of America’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2M Sell
2,359,241
-28,345
-1% -$66.7K ﹤0.01% 3303
2025
Q4 		$4.56M Buy
2,387,586
+334,424
+16% +$792K ﹤0.01% 3469
2025
Q3 		$4.56M Buy
2,053,162
+45,158
+2% +$108K ﹤0.01% 4105
2025
Q2 		$2.87M Buy
2,008,004
+17,180
+0.9% +$25K ﹤0.01% 4428
2025
Q1 		$3.19M Buy
1,990,824
+313,182
+19% +$934K ﹤0.01% 4256
2024
Q4 		$6.04M Sell
1,677,642
-358,591
-18% -$1.78M ﹤0.01% 3406
2024
Q3 		$11.6M Buy
2,036,233
+267,734
+15% +$1.61M ﹤0.01% 2929
2024
Q2 		$8.17M Sell
1,768,499
-86,659
-5% -$517K ﹤0.01% 3156
2024
Q1 		$15.2M Buy
1,855,158
+180,061
+11% +$1.4M ﹤0.01% 2555
2023
Q4 		$9.46M Buy
1,675,097
+1,629,756
+3,594% +$3.72M ﹤0.01% 2949
2023
Q3 		$84.3K Buy
45,341
+11,672
+35% +$35.6K ﹤0.01% 6316
2023
Q2 		$92.6K Sell
33,669
-17,819
-35% -$57.3K ﹤0.01% 6237
2023
Q1 		$162K Sell
51,488
-143,668
-74% -$846K ﹤0.01% 6030
2022
Q4 		$1.15M Buy
195,156
+55,969
+40% +$464K ﹤0.01% 4732
2022
Q3 		$1.22M Buy
139,187
+77,676
+126% +$806K ﹤0.01% 4724
2022
Q2 		$464K Sell
61,511
-42,267
-41% -$372K ﹤0.01% 5480
2022
Q1 		$2.52M Buy
103,778
+2,105
+2% +$51.1K ﹤0.01% 4366
2021
Q4 		$3.27M Buy
101,673
+80,122
+372% +$3.17M ﹤0.01% 4069
2021
Q3 		$963K Sell
21,551
-12,754
-37% -$546K ﹤0.01% 5124
2021
Q2 		$1.3M Sell
34,305
-14,469
-30% -$518K ﹤0.01% 4673
2021
Q1 		$1.8M Buy
48,774
+42,644
+696% +$1.7M ﹤0.01% 4354
2020
Q4 		$203K Buy
+6,130
New +$178K ﹤0.01% 5592

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America's CCCC Position: Q1 2026 in Review

Bank of America reduced its C4 Therapeutics (CCCC) stake by 1.2% in Q1 2026, selling an estimated $66.7K and leaving 2,359,241 shares worth $6.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3303.

Bank of America first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $15.2M in Q1 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Bank of America held 2,359,241 shares of C4 Therapeutics worth $6.2M as of Q1 2026.
  • Bank of America sold 28,345 C4 Therapeutics shares in Q1 2026, an estimated $66.7K.
  • C4 Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3303 holding.
  • Bank of America first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Bank of America's C4 Therapeutics position peaked at $15.2M in Q1 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.